Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer
B Alagesan, G Contino, AR Guimaraes… - Clinical cancer …, 2015 - AACR
… MEK/PI3K inhibition in pancreatic ductal adenocarcinoma (PDAC). MEK inhibitors were the
… screen of 50 clinically relevant drugs in >500 human cancer cell lines. In combination with …
… screen of 50 clinically relevant drugs in >500 human cancer cell lines. In combination with …
Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer
… PI3K inhibitor, LY294002, or transfection of a dominant negative mutant of Akt, inhibited
IKK and NF-κB activity in pancreatic cancer … NF-κB in pancreatic cancer cell lines was Akt/PI3K- …
IKK and NF-κB activity in pancreatic cancer … NF-κB in pancreatic cancer cell lines was Akt/PI3K- …
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
R Baer, C Cintas, N Therville… - Advances in biological …, 2015 - Elsevier
… particular Class I PI3K isoforms for pancreatic cancer treatment. Isoform-specificity of PI3K
inhibitors are currently designed to achieve the same goal as pan-PI3K inhibitors but without …
inhibitors are currently designed to achieve the same goal as pan-PI3K inhibitors but without …
[HTML][HTML] Targeting PI3K/AKT/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects
S Stanciu, F Ionita-Radu, C Stefani, D Miricescu… - International journal of …, 2022 - mdpi.com
… -0941, RG7621), a pan-Pi3K inhibitor, had minimal antitumor efficiency and was not well …
treating pancreatic cancer patients. In this review, we focus on PI3K/AKT/mTOR inhibitors that …
treating pancreatic cancer patients. In this review, we focus on PI3K/AKT/mTOR inhibitors that …
[HTML][HTML] PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells
Y Wang, Y Kuramitsu, B Baron… - International …, 2016 - spandidos-publications.com
… , as it improved the anticancer drug efficacy by inhibiting the PI3K … , the PI3K inhibitor
LY294002 has been shown to enhance PI3K-dependent AKT phosphorylation in pancreatic cancer …
LY294002 has been shown to enhance PI3K-dependent AKT phosphorylation in pancreatic cancer …
Concurrent HER or PI3K inhibition potentiates the antitumor effect of the ERK inhibitor ulixertinib in preclinical pancreatic cancer models
H Jiang, M Xu, L Li, P Grierson, P Dodhiawala… - Molecular cancer …, 2018 - AACR
… of ERK1/2, MEK, and the parallel PI3K–AKT pathways, partly through engagement of the …
to tolerate ERK inhibition. Supporting this notion, we showed that pan-HER and PI3K inhibitors …
to tolerate ERK inhibition. Supporting this notion, we showed that pan-HER and PI3K inhibitors …
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
… More recently, olaparib, a PARP inhibitor, has received FDA approval for pancreatic cancer
patients harboring germline BRCA1 or BRCA2 mutations, presenting the first biomarker-…
patients harboring germline BRCA1 or BRCA2 mutations, presenting the first biomarker-…
[HTML][HTML] HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer
M Rumman, KH Jung, Z Fang, HH Yan, MK Son… - Oncotarget, 2016 - ncbi.nlm.nih.gov
… for treating pancreatic cancer patients with … , a PI3K inhibitor on the EMT in pancreatic cancer
and to identify its possible mechanism of action. Herein, we found that HS-173 inhibited TGF…
and to identify its possible mechanism of action. Herein, we found that HS-173 inhibited TGF…
[HTML][HTML] PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
SN Payne, ME Maher, NH Tran, DR Van De Hey… - Oncogenesis, 2015 - nature.com
… discovery of a subtype of pancreatic adenocarcinoma that might be … PI3K in the pancreas
and examine the response of PIK3CA mutant pancreatic cancer to dual PI3K/mTOR inhibition…
and examine the response of PIK3CA mutant pancreatic cancer to dual PI3K/mTOR inhibition…
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
JRW Conway, D Herrmann, TRJ Evans, JP Morton… - Gut, 2019 - gut.bmj.com
… cell proliferation to the same degree as PI3K pathway inhibitors, indicating that multiple
RTK pathways feed into PI3K activation in PDAC and that PI3K inhibition may provide an …
RTK pathways feed into PI3K activation in PDAC and that PI3K inhibition may provide an …
相关搜索
- pancreatic cancer pi3k pathway inhibitors
- pancreatic cancer cells
- pancreatic cancer pi3k akt mtor pathway
- preclinical models of pancreatic cancer
- pancreatic cancer mouse model
- gemcitabine in pancreatic cancer
- adverse effects pi3k inhibitors in cancer
- pancreatic cancer xenografts mek inhibitor trametinib
- pi3k inhibitor metastasis in pancreatic cancer
- pancreatic cancer invasion pi3k and mapk
- targeted inhibition human pancreatic cancer
- akt pi3k treatment of pancreatic cancer
- pi3k inhibitor human pancreatic adenocarcinoma cells
- pancreatic tumorigenesis pi3k inhibitors
- pancreatic cancer dominant negative inhibitors
- clinical implications pi3k inhibitors in cancer